Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines-Reference-Cited by-同舟云学术

Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines

Published:2011-03 Issue:5 Volume:81 Page:586-593
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Bastin-Coyette L.,Cardoen S.,Smal C.,de Viron E.,Arts A.,Amsailale R.,Van Den Neste E.,Bontemps F.

Funder

Belgian Fonds National de la Recherche Scientifique

Interuniversity Attraction Poles Program-Belgian Science Policy

DIANE Centre of Excellence Programme of the Région Wallonne

Maisin, Goor, and Salus Sanguinis

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference64 articles.

1. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies;Robak;Drugs Aging,2005

2. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review);Van den Neste;Int J Oncol,2005

3. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases;Robak;Molecules,2009

4. Mechanism of action of purine analogues in chronic lymphocytic leukaemia;Pettitt;Br J Haematol,2003

5. Nucleoside analogs: molecular mechanisms signaling cell death;Ewald;Oncogene,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial Effect of Olive Oil and Its Derivates: Focus on Hematological Neoplasm;Life;2024-04-30

2. The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomized Trial;Frontiers in Oncology;2022-01-21

3. Cherenkov counting;Handbook of Radioactivity Analysis: Volume 2;2020

4. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1;Proceedings of the National Academy of Sciences;2018-10-10

5. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1;2018-04-06